Glucotrack to present first-in-human CBGM data at ADA 85th Scientific Sessions

Glucotrack, Inc.

Will present safety & performance data from first-in-human trial of implantable continuous blood glucose monitor (CBGM).
Live presentation by CSO Mark Tapsak on June 21 in Innovation Hub; poster session June 22.
CBGM measures glucose directly from blood, lasts up to 3 years, no on-body wearable.
Company preparing for next clinical phase (long-term feasibility study).

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.